[go: up one dir, main page]

SI3159329T1 - Uporaba 2-hidroksi derivatov polinenasičenih maščobnih kislin kot zdravila - Google Patents

Uporaba 2-hidroksi derivatov polinenasičenih maščobnih kislin kot zdravila

Info

Publication number
SI3159329T1
SI3159329T1 SI201032041T SI201032041T SI3159329T1 SI 3159329 T1 SI3159329 T1 SI 3159329T1 SI 201032041 T SI201032041 T SI 201032041T SI 201032041 T SI201032041 T SI 201032041T SI 3159329 T1 SI3159329 T1 SI 3159329T1
Authority
SI
Slovenia
Prior art keywords
hidroxyderivates
medicaments
fatty acids
polyunsaturated fatty
polyunsaturated
Prior art date
Application number
SI201032041T
Other languages
English (en)
Inventor
Ruiz Pablo Vicente Escriba
Xaubet Xavier Busquets
Jimenez Silvia Teres
Coblijn Gwendolyn Barcelo
Canellas Victoria Llado
Etxenike Amaia Marcilla
Maria Laura Martin
Urbano Monica Higuera
Martinez Rafael Alvarez
Daniel Horacio Lopez
Castillo Catalina Ana Rosello
Garcia Paula Fernandez
Canalejo Manuel Torres
Original Assignee
Lipopharma Therapeutics, S.L.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopharma Therapeutics, S.L., filed Critical Lipopharma Therapeutics, S.L.,
Publication of SI3159329T1 publication Critical patent/SI3159329T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201032041T 2009-03-16 2010-03-15 Uporaba 2-hidroksi derivatov polinenasičenih maščobnih kislin kot zdravila SI3159329T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200900725A ES2345241B1 (es) 2009-03-16 2009-03-16 Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
EP16201132.4A EP3159329B1 (en) 2009-03-16 2010-03-15 Use of 2-hidroxyderivates of polyunsaturated fatty acids as medicaments

Publications (1)

Publication Number Publication Date
SI3159329T1 true SI3159329T1 (sl) 2021-01-29

Family

ID=42673244

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201032041T SI3159329T1 (sl) 2009-03-16 2010-03-15 Uporaba 2-hidroksi derivatov polinenasičenih maščobnih kislin kot zdravila

Country Status (19)

Country Link
US (7) US9161928B2 (sl)
EP (2) EP2409963B1 (sl)
JP (1) JP5904592B2 (sl)
KR (4) KR101833772B1 (sl)
CN (4) CN109999018A (sl)
AU (6) AU2010224749B2 (sl)
BR (1) BRPI1009860A8 (sl)
CA (1) CA2754963C (sl)
CL (1) CL2011002268A1 (sl)
DK (2) DK3159329T3 (sl)
ES (3) ES2345241B1 (sl)
HK (1) HK1232207A1 (sl)
HU (2) HUE032027T2 (sl)
MX (1) MX2011009614A (sl)
PL (1) PL2409963T3 (sl)
PT (2) PT3159329T (sl)
RU (1) RU2513995C2 (sl)
SI (1) SI3159329T1 (sl)
WO (1) WO2010106211A1 (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
CA3083907A1 (en) 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
WO2012148929A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Disorders implicating pufa oxidation
KR102112087B1 (ko) 2011-04-26 2020-05-18 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
AU2012249921B2 (en) 2011-04-26 2017-06-08 Biojiva Llc Oxidative retinal diseases
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
KR101970151B1 (ko) * 2014-10-21 2019-04-19 유니버시다드 데 레스 일레스 발레아르스 하이드록시-트리글리세라이드의 합성 방법 및 질병의 예방 및 치료에 사용되는 하이드록시-트리글리세라이드의 용도
US20180024150A1 (en) * 2015-03-06 2018-01-25 Niigata University Biomarker of dementia with lewy bodies
CN108698987B (zh) 2015-11-23 2021-07-13 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
MX2019013683A (es) * 2017-05-16 2020-01-15 Ability Pharmaceuticals Sl Una combinacion farmaceutica para el tratamiento de un cancer.
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
CA3163680A1 (en) 2019-12-05 2021-06-10 David John O'neill Rapamycin analogs and uses thereof
AU2021212330A1 (en) * 2020-01-29 2022-09-22 Universitat De Les Illes Balears Alpha-hydroxylated fatty-acid metabolites, medical uses of same and use as biomarkers
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
CA3163864A1 (en) 2020-02-10 2021-08-19 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717816D0 (en) 1987-07-28 1987-09-03 Manchester Inst Science Tech Fabric testing apparatus
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH05974A (ja) * 1991-06-21 1993-01-08 Sagami Chem Res Center ハロゲン化不飽和アルキル化合物及びその前駆体
ES2161146B1 (es) * 1999-06-29 2002-07-01 Consejo Superior Investigacion Compuestos antimicrobianos, uso y metodo para inducir resistencia a infecciones de bacterias en plantas.
US6344574B1 (en) * 2000-07-20 2002-02-05 The United States Of America As Represented By The Secretary Of Agriculture Solvent fractionation of chicken fat for making lipid compositions enriched in unsaturated fatty acid-containing triacylglycerols
DE10106660A1 (de) * 2001-02-12 2002-08-29 Celanese Ventures Gmbh Verfahren zur Herstellung von gamma-Linolensäure aus einer Ciliaten-Kultur durch Zusatz geeigneter Vorläufermoleküle zu dem Kulturmedium
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
SI2022775T1 (sl) * 2002-04-01 2015-03-31 University Of Southern California Trihidroksi polinenasiäśeni eikosanoidi
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EA010802B1 (ru) * 2004-11-19 2008-12-30 Мартек Байосайенсиз Корпорейшн Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
GB0428384D0 (en) 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1888727B1 (en) * 2005-05-04 2015-04-15 Pronova BioPharma Norge AS New dha derivatives and their use as medicaments
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
US8059805B2 (en) * 2005-06-30 2011-11-15 Emc Corporation Enhanced services provided using communication redirection and processing
JP2009502745A (ja) 2005-07-08 2009-01-29 マーテック バイオサイエンシーズ コーポレーション 認知症および前認知症に関連した状態を治療するための多価不飽和脂肪酸
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
RU2009120568A (ru) 2006-11-01 2010-12-10 Пронова Биофарма Норге Ас (No) Композиция
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.

Also Published As

Publication number Publication date
CN109999018A (zh) 2019-07-12
CN102356057A (zh) 2012-02-15
HUE032027T2 (en) 2017-08-28
ES2345241B1 (es) 2011-09-08
US10201515B2 (en) 2019-02-12
CA2754963C (en) 2022-02-08
JP5904592B2 (ja) 2016-04-13
EP3159329A1 (en) 2017-04-26
AU2018203976A1 (en) 2018-06-21
RU2011141850A (ru) 2013-04-27
DK3159329T3 (da) 2020-11-09
US11253497B2 (en) 2022-02-22
US20200352891A1 (en) 2020-11-12
HUE051850T2 (hu) 2021-03-29
BRPI1009860A2 (pt) 2016-03-08
AU2019226257B2 (en) 2020-05-07
CA2754963A1 (en) 2010-09-23
US20160158181A1 (en) 2016-06-09
AU2016238970B2 (en) 2018-03-08
AU2020205214A1 (en) 2020-07-30
CN106420686B (zh) 2020-05-22
AU2020205213A1 (en) 2020-07-30
AU2020205213B2 (en) 2021-02-25
US20170035720A1 (en) 2017-02-09
ES2613606T3 (es) 2017-05-24
EP2409963A4 (en) 2013-10-02
KR102233102B1 (ko) 2021-03-26
ES2345241A1 (es) 2010-09-17
CN106349058B (zh) 2020-01-14
CN106420686A (zh) 2017-02-22
AU2016238970A1 (en) 2016-11-03
US9763906B2 (en) 2017-09-19
AU2018203976B2 (en) 2019-06-06
AU2019226257A1 (en) 2019-09-26
AU2010224749B2 (en) 2016-07-07
US9763907B2 (en) 2017-09-19
US20160158180A1 (en) 2016-06-09
US9161928B2 (en) 2015-10-20
WO2010106211A1 (es) 2010-09-23
RU2513995C2 (ru) 2014-04-27
BRPI1009860A8 (pt) 2019-12-17
KR20200024953A (ko) 2020-03-09
DK2409963T3 (en) 2017-02-27
KR101833772B1 (ko) 2018-03-02
KR20180021931A (ko) 2018-03-05
HK1232207A1 (zh) 2018-01-05
AU2010224749A1 (en) 2011-10-13
AU2020205214B2 (en) 2021-02-18
EP3159329B1 (en) 2020-08-12
EP2409963A1 (en) 2012-01-25
KR20110137365A (ko) 2011-12-22
US20180085332A1 (en) 2018-03-29
MX2011009614A (es) 2012-01-20
KR20190018754A (ko) 2019-02-25
CL2011002268A1 (es) 2012-01-27
EP2409963B1 (en) 2017-01-04
JP2012520344A (ja) 2012-09-06
US9907772B2 (en) 2018-03-06
ES2820025T3 (es) 2021-04-19
CN106349058A (zh) 2017-01-25
US20190365690A1 (en) 2019-12-05
US20120108550A1 (en) 2012-05-03
PT2409963T (pt) 2017-02-15
PT3159329T (pt) 2020-11-13
PL2409963T3 (pl) 2017-05-31

Similar Documents

Publication Publication Date Title
HK1232207A1 (zh) 多不飽和脂肪酸的衍生物作為藥物的用途
EP2498602A4 (en) STABILIZED FORMULATIONS FROM FATTY ACIDS
EP2425007A4 (en) PREPARATION OF FATTY ACID ESTERS
IL212112A0 (en) Production of modifird fatty acids in plants
EP2521447A4 (en) FATTY FATTY ACID DERIVATIVES AND USES THEREOF
PH12012500561A1 (en) Production of fatty acid derivatives
EP2417246A4 (en) PRODUCTION OF FATTY ACID DERIVATIVES
EP2483233A4 (en) HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
ZA201104036B (en) Fatty acids for use as a medicament
ZA201403784B (en) Compositions comprising 20-carbon fatty acids and methods of making and using same
IL213354A (en) Alpha-monoclonal fatty acid alpha history for use as a drug
PT2528889T (pt) Processo para preparar e purificar ácidos gordos
IL214887A0 (en) Fatty acid monoglyceride compositions
GB201304550D0 (en) Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof
EP2726086A4 (en) COMPOSITIONS CONTAINING FATTY NITROACIDS
IL219958A0 (en) Omega-3 fatty acid enriched meat compositions
HK1185806A1 (zh) 含有多不飽和脂肪酸的組合物
GB0904300D0 (en) Essential fatty acid compounds
AU2010903057A0 (en) Acetylenation of fatty acids
GB201021862D0 (en) Improvements in the manufacture of fatty acids